Consistent with this observation, mutation/amplification of genes involved in cell-cycle control, including CCND1, have also been suggested to hinder the therapeutic effects of EGFR TKIs in NSCLC (34). This evidence concerns the gene CCND1 and non-small cell lung carcinoma.